Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 05:36:25 GMT 2025
by
admin
on
Wed Apr 02 05:36:25 GMT 2025
|
| Protein Type | stimulating factor |
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
M65IE9C8XJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M65IE9C8XJ
Created by
admin on Wed Apr 02 05:36:25 GMT 2025 , Edited by admin on Wed Apr 02 05:36:25 GMT 2025
|
PRIMARY | |||
|
M65IE9C8XJ
Created by
admin on Wed Apr 02 05:36:25 GMT 2025 , Edited by admin on Wed Apr 02 05:36:25 GMT 2025
|
PRIMARY | |||
|
2619327
Created by
admin on Wed Apr 02 05:36:25 GMT 2025 , Edited by admin on Wed Apr 02 05:36:25 GMT 2025
|
PRIMARY |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_182 |
| N | 1_1135 |
| N | 2_182 |
| N | 2_1135 |
| O | 1_99 |
| O | 1_112 |
| O | 1_216 |
| O | 1_229 |
| O | 1_253 |
| O | 1_267 |
| O | 1_281 |
| O | 1_282 |
| O | 1_286 |
| O | 1_293 |
| O | 1_300 |
| O | 1_308 |
| O | 1_314 |
| O | 1_343 |
| O | 1_349 |
| O | 1_352 |
| O | 1_360 |
| O | 1_361 |
| O | 1_364 |
| O | 1_367 |
| O | 1_375 |
| O | 1_376 |
| O | 1_383 |
| O | 1_384 |
| O | 1_391 |
| O | 1_399 |
| O | 1_403 |
| O | 1_406 |
| O | 1_414 |
| O | 1_415 |
| O | 1_422 |
| O | 1_423 |
| O | 1_430 |
| O | 1_431 |
| O | 1_453 |
| O | 1_454 |
| O | 1_461 |
| O | 1_469 |
| O | 1_470 |
| O | 1_477 |
| O | 1_478 |
| O | 1_485 |
| O | 1_501 |
| O | 1_505 |
| O | 1_508 |
| O | 1_516 |
| O | 1_517 |
| O | 1_529 |
| O | 1_531 |
| O | 1_539 |
| O | 1_540 |
| O | 1_547 |
| O | 1_548 |
| O | 1_555 |
| O | 1_556 |
| O | 1_563 |
| O | 1_564 |
| O | 1_571 |
| O | 1_579 |
| O | 1_580 |
| O | 1_587 |
| O | 1_588 |
| O | 1_592 |
| O | 1_595 |
| O | 1_603 |
| O | 1_652 |
| O | 1_659 |
| O | 1_660 |
| O | 1_667 |
| O | 1_668 |
| O | 1_675 |
| O | 1_676 |
| O | 1_680 |
| O | 1_683 |
| O | 1_699 |
| O | 1_700 |
| O | 1_712 |
| O | 1_744 |
| O | 1_745 |
| O | 1_752 |
| O | 1_753 |
| O | 1_768 |
| O | 1_769 |
| O | 1_781 |
| O | 1_788 |
| O | 1_805 |
| O | 1_813 |
| O | 1_814 |
| O | 1_868 |
| O | 1_876 |
| O | 1_906 |
| O | 1_907 |
| O | 1_938 |
| O | 1_939 |
| O | 1_944 |
| O | 1_951 |
| O | 1_954 |
| O | 1_955 |
| O | 1_956 |
| O | 1_1015 |
| O | 1_1137 |
| O | 2_99 |
| O | 2_112 |
| O | 2_216 |
| O | 2_229 |
| O | 2_253 |
| O | 2_267 |
| O | 2_281 |
| O | 2_282 |
| O | 2_286 |
| O | 2_293 |
| O | 2_300 |
| O | 2_308 |
| O | 2_314 |
| O | 2_343 |
| O | 2_349 |
| O | 2_352 |
| O | 2_360 |
| O | 2_361 |
| O | 2_364 |
| O | 2_367 |
| O | 2_375 |
| O | 2_376 |
| O | 2_383 |
| O | 2_384 |
| O | 2_391 |
| O | 2_399 |
| O | 2_403 |
| O | 2_406 |
| O | 2_414 |
| O | 2_415 |
| O | 2_422 |
| O | 2_423 |
| O | 2_430 |
| O | 2_431 |
| O | 2_453 |
| O | 2_454 |
| O | 2_461 |
| O | 2_469 |
| O | 2_470 |
| O | 2_477 |
| O | 2_478 |
| O | 2_485 |
| O | 2_501 |
| O | 2_505 |
| O | 2_508 |
| O | 2_516 |
| O | 2_517 |
| O | 2_529 |
| O | 2_531 |
| O | 2_539 |
| O | 2_540 |
| O | 2_547 |
| O | 2_548 |
| O | 2_555 |
| O | 2_556 |
| O | 2_563 |
| O | 2_564 |
| O | 2_571 |
| O | 2_579 |
| O | 2_580 |
| O | 2_587 |
| O | 2_588 |
| O | 2_592 |
| O | 2_595 |
| O | 2_603 |
| O | 2_652 |
| O | 2_659 |
| O | 2_660 |
| O | 2_667 |
| O | 2_668 |
| O | 2_675 |
| O | 2_676 |
| O | 2_680 |
| O | 2_683 |
| O | 2_699 |
| O | 2_700 |
| O | 2_712 |
| O | 2_744 |
| O | 2_745 |
| O | 2_752 |
| O | 2_753 |
| O | 2_768 |
| O | 2_769 |
| O | 2_781 |
| O | 2_788 |
| O | 2_805 |
| O | 2_813 |
| O | 2_814 |
| O | 2_868 |
| O | 2_876 |
| O | 2_906 |
| O | 2_907 |
| O | 2_938 |
| O | 2_939 |
| O | 2_944 |
| O | 2_951 |
| O | 2_954 |
| O | 2_955 |
| O | 2_956 |
| O | 2_1015 |
| O | 2_1137 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVATOR OF EXPRESSION->TARGET |
Increased expression of PRG4 mRNA in tendons treated with rabPXL01 in HA, but not in tendon sheaths. In addition, treatment with rabPXL01 in HA led to repression of the mRNA levels for the pro-inflammatory mediators interleukin (IL)-1?, IL-6, and IL-8 in tendon sheaths.
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|